Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction chemotherapy followed by cetuximab plus definitive radiotherapy versus radiotherapy plus cisplatin in locally advanced head and neck squamous cell carcinoma
2009-013402-14Phase 3Active
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jul 2009
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab, cisplatin, docetaxel and fluorouracil in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoint: overall survival. Started Jul 2009; status: active.
02
Drugs
cetuximabcisplatindocetaxelfluorouracil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2009-013402-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013402-14.